DEERFIELD, Ill.--(BUSINESS WIRE)--Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS® (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.